Find A Multiple Myeloma Trial

Cervino is a Phase 3 trial for patients with relapsed or refractory multiple myeloma who have received 2 or more prior therapies and have not received a treatment that targets BCMA. The goal of the study is to compare the effectiveness and safety of the investigational BCMA-targeting bispecific antibody, etentamig, to standard treatment options.

The phase 2 TALISMAN study is evaluating how to manage oral side effects from Talquetamab, a bispecific antibody treatment. The study is recruiting participants in the United States with relapsed or refractory multiple myeloma and there are over 8 sites currently open.

This clinical study is testing whether a plant-based diet or special supplements can help people with early stages of multiple myeloma by measuring changes in their gut bacteria. What makes this trial unique is that it's using pre-made plant-based meals delivered weekly and comparing them to omega-3 and curcumin supplements to see which approach works best for potentially preventing the disease from getting worse.

QUINTESSENTIAL-2 is a phase 3 clinical trial for patients with relapsed/refractory multiple myeloma who have had 1 to 3 prior treatments. The goal of this study is to test if an investigational CAR T-cell therapy called Arlocabtagene Autoleucel (arlo-cel) is safer and more effective than standard treatment options. There are more than 10 study sites currently open in the US.

iMMagine-3 is a phase 3, randomized clinical trial for people with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and immunomodulatory drug. The goal of the study is to evaluate if anitocabtagene autoleucel (anito-cel) is more effective than standard of care treatment (PVd, DPd, KDd, or Kd), as measured by progression free survival (the amount of time before the disease worsens).

LINKER-MM4 is a clinical trial for people with newly diagnosed multiple myeloma. This study is looking at how safe Lynozyfic (linvoseltamab) is, how well patients can tolerate it, and whether it can be an effective early treatment option for newly diagnosed patients.

The goal of this 20-week study is to see if a digital wellness app can help improve sleep, immune function, and other behavior outcomes for people diagnosed with blood cancers like multiple myeloma. Participants will use one of two digital wellness apps 10 minutes per day over 8-weeks to determine how well the app works. This study is completely remote (no in-person visits) and patients from across the USA are invited. Enrolled participants will be compensated.